Quest
In Brief This Week: Qiagen, Mainz Biomed, Quest Diagnostics, Haystack Oncology, Becton Dickinson
News items for the week of June 19, 2023
Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology for up to $450M
The lab testing giant will add Haystack's minimal residual disease technology to its suite of genomic and other clinical services.
Quest Adds to Cancer Portfolio With $450M Buy of Haystack Oncology; Q1 Revenues Down 11 Percent
Premium
The firm said the acquisition let it move into the "fast growing" MRD space and round out its offerings in cancer screening, pathology, and sequencing.
Quest Diagnostics Gets FDA Emergency Use Authorization for COVID-19 Sample Collection Kit
The kit includes materials for the collection and storage of molecular testing samples, as well as instructions for the drop-off of the specimens.
Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment
Agilent's companion diagnostic for Mirati's non-small cell lung cancer treatment Krazati will be available through Quest's national healthcare network.
Nov 11, 2022
Oct 20, 2022